Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kangmei Pharmaceutical Co has the GF Score of 48, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Kangmei Pharmaceutical Co
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Kangmei Pharmaceutical Co (SHSE:600518) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Kangmei Pharmaceutical Co GF Score Related Terms
SHSE:600518 vs ZTS: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kangmei Pharmaceutical Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kangmei Pharmaceutical Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kangmei Pharmaceutical Co's GF Score distribution charts can be found below:
* The bar in red indicates where Kangmei Pharmaceutical Co's GF Score falls into.
Kangmei Pharmaceutical Co (SHSE:600518) has a GF Score of 48 as of Jul. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Kangmei Pharmaceutical Co and its competitors. This is 27% below median its historical median of 66.00. Over the past decade, Kangmei Pharmaceutical Co's GF Score has ranged from 39.00 to 98.00.
Is Kangmei Pharmaceutical Co's GF Score too high?
Kangmei Pharmaceutical Co's current GF Score of 48 is 27% below median its 10-year median of 66.00. Over the past 10 years, this metric has ranged from a low of 39.00 to a high of 98.00. Overall, Kangmei Pharmaceutical Co has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kangmei Pharmaceutical Co's GF Score compare to ZTS?
Kangmei Pharmaceutical Co's GF Score of 48 can be compared against companies in the Drug Manufacturers industry. Historically, Kangmei Pharmaceutical Co's own GF Score has ranged from 39.00 to 98.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Kangmei Pharmaceutical Co and its competitors. Kangmei Pharmaceutical Co's current GF Score is 48, which is 27% below median its own 10-year median of 66.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kangmei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kangmei Pharmaceutical Co (SHSE:600518) is currently considered Fairly Valued. The stock's GF Value™ is ¥1.46, compared to a current price of ¥1.35 — trading 7.5% below its estimated fair value. The current GF Score is 48, which is 27% below median its 10-year median of 66.00. Kangmei Pharmaceutical Co's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Kangmei Pharmaceutical Co (SHSE:600518), the current GF Score is 48 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kangmei Pharmaceutical Co (SHSE:600518) Overvalued in 2026?
Based on GuruFocus' analysis, Kangmei Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥1.35 is trading 7.5% below its estimated GF Value™ of ¥1.46.
GuruFocus considers Kangmei Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600518:
GF Score: 48 (27% below median its 10-year median of 66.00)
GF Value™: ¥1.46 vs. price of ¥1.35 (7.5% below fair value)
No single metric tells the full story. See the SHSE:600518 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs, and medical devices, modern pharmaceutical logistics system. The company is also engaged in medical equipment, property leasing and sales, and other services.
48GF Score
Get the complete analysis for SHSE:600518
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600518 has been successfully added to your 
